Combination therapy with acarbose in IDDM
Clinical trials in which acarbose was used with other antidiabetic agents for NIDDM are summarized in Table 5. In these trials acarbose was generally added to previous monotherapy consisting of metformin, a sulphonylurea or insulin.
In patients not adequately controlled on either metformin or a sulphonylurea, addition of acarbose produced improvement in glycemic control of a similar magnitude to that observed during its use as monotherapy. In another trial, use of acarbose plus tolbutamide in diet-failed patients was associated with reduced postprandial serum insulin concentration and reduced weight gain versus results from using tolbutamide alone.
Addition ofacarbose in NIDDM patients who are receiving insulin therapy was associated with more modest benefits. The reduction in HbA1c was approximately half that achieved when acarbose was added to previous oral antidiabetic therapy. Addition of acarbose allowed a modest reduction in the average daily insulin requirement.
Acarbose combined with insulin in IDDM
Control of PPG in patients with insulin-dependent diabetes mellitus (IDDM) can be difficult. Absorption of short-acting (regular) insulin following subcutaneous injection is slow and variable. Acarbose may have the potential to ameliorate this problem by blunting the meal-related rise in plasma glucose. The few trials cited in Table 6 indicate a modest, variable improvement in overall glycemic control when acarbose was added to previous insulin therapy. You will always be glad to know there is a perfect pharmacy waiting for you whenever you need allergy treatment and would like to make sure you are taken best care of as a customer and patient.